U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C59H84N18O14
Molecular Weight 1269.4128
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GOSERELIN

SMILES

CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)NNC(N)=O

InChI

InChIKey=BLCLNMBMMGCOAS-URPVMXJPSA-N
InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1

HIDE SMILES / InChI

Molecular Formula C59H84N18O14
Molecular Weight 1269.4128
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/zoladex.html

Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels. Goserelin is used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty. Goserelin is marketed under the brand names Zoladex, by AstraZeneca, or goserelin acetate.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL612518
0.82 nM [IC50]
1.6 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZOLADEX

Approved Use

ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate Use as palliative treatment of advanced carcinoma of the prostate

Launch Date

1997
Palliative
ZOLADEX

Approved Use

ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate Use as palliative treatment of advanced carcinoma of the prostate

Launch Date

1997
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.79 μg/L
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
13.9 μg/L
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
7.5 μg/L
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9.5 μg/L
250 μg 1 times / day multiple, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: MULTIPLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.84 ng/mL
3.6 mg single, subcutaneous
dose: 3.6 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.46 ng/mL
3.6 mg single, subcutaneous
dose: 3.6 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
8.85 ng/mL
10.8 mg single, subcutaneous
dose: 10.8 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
3 ng/mL
3.6 mg single, subcutaneous
dose: 3.6 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
36.9 μg × h/L
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
41.3 μg × h/L
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
44.5 μg × h/L
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
44 μg × h/L
250 μg 1 times / day multiple, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: MULTIPLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
27.8 ng × day/mL
3.6 mg single, subcutaneous
dose: 3.6 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
18.5 ng × day/mL
3.6 mg single, subcutaneous
dose: 3.6 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.2 h
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.3 h
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
4.6 h
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5 h
250 μg 1 times / day multiple, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: MULTIPLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
73%
10.8 mg single, subcutaneous
dose: 10.8 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Sources:
unhealthy, 18 - 49 years
Health Status: unhealthy
Age Group: 18 - 49 years
Sex: F
Sources:
Other AEs: Fatigue, Hot flashes...
Other AEs:
Fatigue (grade 2, 2 patients)
Hot flashes (grade 2, 29 patients)
Menses irregular (grade 2, 5 patients)
Libido decreased (grade 2, 9 patients)
Agitation (grade 2, 6 patients)
Anxiety (grade 2, 9 patients)
Depression (grade 2, 8 patients)
Muscle pain (grade 2, 1 patient)
Headache (grade 2, 12 patients)
Sweating (grade 2, 10 patients)
Thromboembolism (grade 4, 1 patient)
Dryness vaginal (grade 2, 12 patients)
Hot flashes (grade 3, 4 patients)
Menses irregular (grade 3, 2 patients)
Depression (grade 3, 1 patient)
Sources:
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Sources:
unhealthy, adult
Other AEs: Gastrointestinal disorder (NOS), Bladder disorder NOS...
Other AEs:
Gastrointestinal disorder (NOS) (80%)
Bladder disorder NOS (58%)
Skin and subcutaneous conditions NEC (37%)
Sources:
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Sources:
unhealthy, adult
Other AEs: Diarrhea, Cystitis...
Other AEs:
Diarrhea (36%)
Cystitis (16%)
Bleeding rectal (14%)
Proctitis (8%)
Hematuria (7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Muscle pain grade 2, 1 patient
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Sources:
unhealthy, 18 - 49 years
Health Status: unhealthy
Age Group: 18 - 49 years
Sex: F
Sources:
Sweating grade 2, 10 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Sources:
unhealthy, 18 - 49 years
Health Status: unhealthy
Age Group: 18 - 49 years
Sex: F
Sources:
Dryness vaginal grade 2, 12 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Sources:
unhealthy, 18 - 49 years
Health Status: unhealthy
Age Group: 18 - 49 years
Sex: F
Sources:
Headache grade 2, 12 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Sources:
unhealthy, 18 - 49 years
Health Status: unhealthy
Age Group: 18 - 49 years
Sex: F
Sources:
Fatigue grade 2, 2 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Sources:
unhealthy, 18 - 49 years
Health Status: unhealthy
Age Group: 18 - 49 years
Sex: F
Sources:
Hot flashes grade 2, 29 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Sources:
unhealthy, 18 - 49 years
Health Status: unhealthy
Age Group: 18 - 49 years
Sex: F
Sources:
Menses irregular grade 2, 5 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Sources:
unhealthy, 18 - 49 years
Health Status: unhealthy
Age Group: 18 - 49 years
Sex: F
Sources:
Agitation grade 2, 6 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Sources:
unhealthy, 18 - 49 years
Health Status: unhealthy
Age Group: 18 - 49 years
Sex: F
Sources:
Depression grade 2, 8 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Sources:
unhealthy, 18 - 49 years
Health Status: unhealthy
Age Group: 18 - 49 years
Sex: F
Sources:
Anxiety grade 2, 9 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Sources:
unhealthy, 18 - 49 years
Health Status: unhealthy
Age Group: 18 - 49 years
Sex: F
Sources:
Libido decreased grade 2, 9 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Sources:
unhealthy, 18 - 49 years
Health Status: unhealthy
Age Group: 18 - 49 years
Sex: F
Sources:
Depression grade 3, 1 patient
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Sources:
unhealthy, 18 - 49 years
Health Status: unhealthy
Age Group: 18 - 49 years
Sex: F
Sources:
Menses irregular grade 3, 2 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Sources:
unhealthy, 18 - 49 years
Health Status: unhealthy
Age Group: 18 - 49 years
Sex: F
Sources:
Hot flashes grade 3, 4 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Sources:
unhealthy, 18 - 49 years
Health Status: unhealthy
Age Group: 18 - 49 years
Sex: F
Sources:
Thromboembolism grade 4, 1 patient
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Sources:
unhealthy, 18 - 49 years
Health Status: unhealthy
Age Group: 18 - 49 years
Sex: F
Sources:
Skin and subcutaneous conditions NEC 37%
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Sources:
unhealthy, adult
Bladder disorder NOS 58%
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Sources:
unhealthy, adult
Gastrointestinal disorder (NOS) 80%
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Sources:
unhealthy, adult
Bleeding rectal 14%
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Sources:
unhealthy, adult
Cystitis 16%
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Sources:
unhealthy, adult
Diarrhea 36%
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Sources:
unhealthy, adult
Hematuria 7%
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Sources:
unhealthy, adult
Proctitis 8%
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Sources:
unhealthy, adult
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[Severe toxic hepatitis during flutamide (Eulexin) treatment].
1989 Jan 16
Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy.
1997
Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial.
2002 Sep
Cirrhosis with steatohepatitis following longterm stilboestrol treatment.
2003 Aug
Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.
2004 May
Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report.
2005 Jun
Patents

Sample Use Guides

ZOLADEX (Goserelin), at a dose of 3.6 mg, should be administered subcutaneously every 28 days into the anterior abdominal wall below the navel line using an aseptic technique under the supervision of a physician
Route of Administration: Other
In Vitro Use Guide
Goserelin significantly inhibited LNCaP cell proliferation at doses between 10(-9)-10(-6) M.
Substance Class Chemical
Created
by admin
on Wed Apr 02 07:04:56 GMT 2025
Edited
by admin
on Wed Apr 02 07:04:56 GMT 2025
Record UNII
0F65R8P09N
Record Status FAILED
Record Version
  • Download
Name Type Language
ICI 118,630
Preferred Name English
GOSERELIN
EP   HSDB   INN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
GOSERELIN [HSDB]
Common Name English
Goserelin [WHO-DD]
Common Name English
1-(5-OXO-L-PROLYL-L-HISTIDYL-L-TRYPTOPHYL-L-SERYL-L-TYROSYL-O-TERT-BUTYL-D-SERYL-L-LEUCYL-L-ARGINYL-L-PROLYL)SEMICARBAZIDE
Common Name English
GOSERELIN [EP MONOGRAPH]
Common Name English
LUTEINIZING HORMONE-RELEASING FACTOR (PIG), 6-(O-(1,1-DIMETHYLETHYL)-D-SERINE)-10-DEGLYCINAMIDE-, 2-(AMINOCARBONYL)HYDRAZIDE
Common Name English
goserelin [INN]
Common Name English
GOSERELIN [USAN]
Common Name English
GOSERELIN [MART.]
Common Name English
ICI-118630
Code English
GOSERELIN [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1910
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
LIVERTOX NBK548740
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
NDF-RT N0000175655
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
WHO-VATC QL02AE03
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
WHO-ATC L02AE03
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
NDF-RT N0000175654
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
Code System Code Type Description
DRUG BANK
DB00014
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201247
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY
EPA CompTox
DTXSID7048297
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY
CAS
65807-02-5
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY
HSDB
7606
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY
IUPHAR
3879
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY
DRUG CENTRAL
1327
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY
DAILYMED
0F65R8P09N
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY
EVMPD
SUB07962MIG
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY
PUBCHEM
5311128
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY
FDA UNII
0F65R8P09N
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY
MESH
D017273
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY
SMS_ID
100000084238
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY
WIKIPEDIA
Goserelin
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY
MERCK INDEX
m5832
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY Merck Index
USAN
Z-21
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY
NCI_THESAURUS
C1374
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY
RXCUI
50610
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY RxNorm
INN
5943
Created by admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC